Success Metrics

Clinical Success Rate
50.0%

Based on 1 completed trials

Completion Rate
50%(1/2)
Active Trials
0(0%)
Results Posted
100%(1 trials)
Terminated
1(33%)

Phase Distribution

Ph phase_2
3
100%

Phase Distribution

0

Early Stage

3

Mid Stage

0

Late Stage

Phase Distribution3 total trials
Phase 2Efficacy & side effects
3(100.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

50.0%

1 of 2 finished

Non-Completion Rate

50.0%

1 ended early

Currently Active

0

trials recruiting

Total Trials

3

all time

Status Distribution
Active(1)
Completed(1)
Terminated(1)

Detailed Status

Completed1
Terminated1
Not yet recruiting1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
0
Success Rate
50.0%
Most Advanced
Phase 2

Trials by Phase

Phase 23 (100.0%)

Trials by Status

completed133%
terminated133%
not_yet_recruiting133%

Recent Activity

0 active trials
Showing 3 of 3
not_yet_recruitingphase_2

Testing the Efficacy, Safety, and PK of 20E in Patients With Obesity Who Are Starting Treatment With the GLP-1 Agonist Semaglutide for Weight Loss.

NCT07411378
completedphase_2

A Double-blind, Placebo-controlled, Randomized INTerventional Clinical Trial (SARA-INT)

NCT03452488
terminatedphase_2

Testing the Efficacy and Safety of BIO101 for the Prevention of Respiratory Deterioration in COVID-19 Patients

NCT04472728

Clinical Trials (3)

Showing 3 of 3 trials
NCT07411378Phase 2

Testing the Efficacy, Safety, and PK of 20E in Patients With Obesity Who Are Starting Treatment With the GLP-1 Agonist Semaglutide for Weight Loss.

Not Yet Recruiting
NCT03452488Phase 2

A Double-blind, Placebo-controlled, Randomized INTerventional Clinical Trial (SARA-INT)

Completed
NCT04472728Phase 2

Testing the Efficacy and Safety of BIO101 for the Prevention of Respiratory Deterioration in COVID-19 Patients

Terminated

All 3 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
3